40 results
8-K
EX-99.1
FHTX
Foghorn Therapeutics Inc
6 May 24
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
7:03am
these data demonstrate the potential of our platform to generate novel medicines against very challenging targets, as well as our leadership … opportunities in chromatin regulatory biology.
Strengthened Financial Leadership. In April 2024, Foghorn appointed Kristian Humer as Chief Financial Officer
8-K
EX-99.1
FHTX
Foghorn Therapeutics Inc
16 Apr 24
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
7:01am
Exhibit 99.1
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
CAMBRIDGE, Mass
8-K
EX-99.1
FHTX
Foghorn Therapeutics Inc
3 Jan 24
Foghorn Therapeutics Announces CFO Departure
4:18pm
for his leadership and commitment during his time at Foghorn”, said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. “He has been … a valued member of our leadership team, and we wish him well in the future.”
The Company has commenced a formal search for a successor. Dr. Reine’s
8-K
EX-99.1
y5s5nrv12r
8 Sep 23
Regulation FD Disclosure
7:04am
8-K
EX-99.1
rswk08llv 3l5
8 Aug 23
Foghorn Therapeutics Announces Chief Medical Officer Succession
7:05am
8-K
EX-99.2
aaz di3d8hdurqxju1
4 Aug 23
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
7:05am
8-K
EX-99.1
xp3alf
28 Jun 23
Regulation FD Disclosure
7:05am
8-K
EX-99.1
e01f2qp ps4ame2is
5 Jun 23
Regulation FD Disclosure
7:02am
8-K
EX-99.2
ss8q08haya5dzad nhj
8 May 23
Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
7:03am
8-K
EX-99.2
pdft17fx
8 Nov 22
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update
7:08am
8-K
EX-99.2
lurthwe11zkpce2hwv
26 Oct 22
Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
7:08am
8-K
EX-99.1
vxgcs8mbgv2e
31 Aug 22
Foghorn Therapeutics Announces Change to Board of Directors
4:12pm
8-K
EX-99.2
15cjigra16ym3801
23 Aug 22
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS
7:04am
8-K
EX-99.2
xaexl2wmcjf4wrjs
9 Aug 22
Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update
7:06am
8-K
EX-99.1
rdz fqtq5eknk4glnp
8 Jun 22
Regulation FD Disclosure
7:05am
8-K
EX-99.1
br4evhts0jpay zjco
19 May 22
Regulation FD Disclosure
4:11pm